ADAR2, also designated adenosine deaminase, RNA-specific (RED1), RNA-editing enzyme 1, DRABA2, DRADA2, ADAR2alpha-L1, ADAR2alpha-L2 and ADAR2alpha-L3, mediates RNA editing by destabilizing RNA through deamination of adenosine to inosine. ADAR2 is responsible for pre-mRNA editing of the glutamate receptor subunit B by site-specific deamination of adenosines. It can modify its own pre-mRNA and generate new splice sites. Translocation of endogenous ADAR2 from the nucleolus to the nucleoplasm results in increased editing of endogenous ADAR2 substrates. Alternative splicing of this gene results in several transcript variants that may influence RNA editing. RNA editing involves the deamination of adenosines at specific sites, the result of which can be a change in the amino acid sequence of the protein so that it differs from that predicted by the sequence of the DNA.
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Formulierung:
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Application Verdünnung:
WB: 1:500~1:1000 IHC: 1:50~1:200
Anwendungsbeschreibung:
ADAR2 (R510) polyclonal antibody detects endogenous levels of ADAR2 protein.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
